Abstract
Background
Obstructive sleep apnea (OSA) is a prevalent condition that is strongly associated with significant cardiovascular comorbidities and a predictor of poor outcomes, particularly in the postsurgical population. There are limited data for venous thromboembolism (VTE) in post-total hip arthroplasty (THA) patients and examining this association in an observational model can be challenging without a significant number of patients.
Methods
As part of this retrospective multicentric cohort study, we queried the TriNetX U.S. Collaborative Network, a deidentified, aggregated electronic health record (EHR) platform containing of over 110 million patients inside the United States. We assessed patients who underwent Current Procedural Terminology (CPT)-coded THA surgery between October 1st 2015 and February 1st 2025 for those patients with ≥2 occurrences of the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) encounter diagnosis codes for OSA (G47.33) in their records and ≥1 occurrence preceding THA). We examined the 28-day incidence of VTE and secondarily its constituents, deep vein thrombosis (DVT), pulmonary embolism (PE), as well as cerebrovascular accident (CVA) and myocardial infarction (MI), in addition to multiple demographic and comorbidity data with which an in-platform propensity score-matched (PSM) analysis was conducted to identify matching controls (without OSA diagnoses).
Results
Out of 180,734 patients who underwent THA in the time period assessed, 33,938 had a preceding OSA diagnosis, while 146,794 had no OSA diagnosis at any time point. Prior to PSM, the OSA cohort carried a significantly higher risk of all outcomes assessed (VTE, DVT, PE, CVA, and MI) in the 28 days following THA surgery. Following PSM, OSA remained significantly associated with VTE (relative risk 1.31, 95% CI 1.15 – 1.50) as well as the secondary outcomes of DVT, PE, and CVA.
Conclusions
These findings further support the association of OSA with post-hip arthroplasty VTE, with increased rates of the latter persisting even after extensive propensity matching for associated comorbidities. Further investigation to discern the underlying pathophysiology of this correlation is necessary.
Keywords: obstructive sleep apnea, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism
Introduction
Obstructive sleep apnea (OSA) is a chronic disorder characterized by recurrent collapse of the upper airway during sleep resulting in brief arousals from sleep often accompanied by oxyhemoglobin desaturation. OSA is most commonly defined by the presence of symptoms of sleep-related breathing disturbance (e.g., snoring) and/or excessive daytime sleepiness in addition to an apnea-hypopnea index (AHI; the number of respiratory events per hour of sleep) ≥ 5, or an AHI ≥15 in the absence of symptoms.1
OSA is estimated to be both highly prevalent and underdiagnosed.2 In the United States, the disease affects 10% of men and 3% of women in the 4th and 5th decades of life and close to 20% of men and 10% of women in the 6th and 7th decades.2 Aside from sex and age, OSA is strongly associated with obesity, to which upward of 60% of cases have been attributed.3 OSA has been found to be an independent predictor for the development of other conditions, such as cerebrovascular accidents (CVA), as well as for poor postsurgical outcomes.1,4,5
Total hip arthroplasty (THA) is one of the most common elective surgical procedures, with a case volume estimated to reach close to 600,000 annually by 2030, with peak occurrence in the 55- to 64-year-old age bracket.6 Among the potential complications of this procedure, postoperative venous thromboembolic disease (VTE) is associated with some of the highest mortality rates.7 In the era of thromboembolic prophylactic strategies, the incidence of symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE) following THA have been estimated to be 0.26% and 0.15%, respectively.6,8
For over two decades, OSA has been reported as an independent risk factor for VTE.9–15 Arnulf et al described in 2002 their observation of 68 patients admitted for VTE having a markedly higher prevalence of OSA than the general population (63% had an AHI >15).11 In 2010, Epstein et al reported patients with confirmed acute PE were significantly more likely to have OSA than those in whom this diagnosis was suspected but ruled out (65% vs 36%, adjusted OR 2.78, 95% CI 1.54 – 5.03, p = 0.001), independent of traditional PE risk factors.13 These findings were further substantiated by later observational studies.12,14,15
Previous work has also suggested OSA may be an independent risk factor for VTE following joint arthroplasty.16,17 We recently reported the association between OSA and VTE in the postoperative period following total knee arthroplasty.18 We hypothesized that there would also be an association between OSA and VTE in THA patients, and sought to assess this association by examining a large, up-to-date sample with propensity matching for OSA.
Methods
As part of this retrospective multicentric cohort study, we queried the TriNetX Analytics (Cambridge, MA) data platform’s U.S. Collaborative Network, a large collection of aggregated and de-identified electronic health record (EHR) data of over 110 million patients in the United States.19,20 All diagnoses and procedures within the TriNetX platform represent encounter diagnosis data derived from participating healthcare organizations’ EHR systems, reflecting clinical documentation that has been harmonized to the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM).20,21 We previously used the TriNetX platform to perform retrospective cohort studies in different populations,22 including patients diagnosed with OSA.18,23 Using in-platform analytics, we assessed patients with a Current Procedural Terminology® (CPT) code corresponding to THA (CPT 27130) procedures taking place between October 1st 2015 and February 1st 2025. From this population, we established two cohorts, patients with OSA diagnosed prior to THA surgery and those without any OSA diagnosis during the study period. To enhance diagnostic specificity of OSA status, we required the OSA cohort to have at least two occurrences of the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) encounter diagnosis codes for OSA (G47.33) in their records, with at least one occurrence preceding the THA procedure (Figure 1). Patients with OSA diagnoses subsequent to THA but not before were excluded, as were those with only one occurrence of the OSA diagnostic code. The exclusion of patients with only a single occurrence of the OSA diagnostic code from the OSA cohort was made prior to the start of the study. This decision was based on prior research demonstrating the poor positive predictive value of single ICD-10-CM encounter diagnostic code occurrence for OSA, compared with substantially improved positive predictive value and specificity with ≥2 occurrences.24–26
Figure 1.

Patient flowchart illustrating cohort definitions. Abbreviations: OSA – obstructive sleep apnea; PSM – propensity score matching, and THA – total hip arthroplasty.
We collected comprehensive demographic and clinical data including age at surgery, sex, and race and ethnicity studied as a binary variable (White and non-White) as obtained from structured EHR demographic fields within the TriNetX data platform. Multiple comorbidities were identified through ICD-10-CM encounter diagnosis codes: hypertension (ICD-10-CM I10), heart failure (I50), atrial fibrillation and flutter (I48), chronic kidney disease (N18), chronic obstructive pulmonary disease (J44), tobacco use (Z72.0), hyperlipidemia (E78), liver disease (both cirrhosis [K74] and nonalcoholic fatty liver disease [K76.0]), neoplasia (C00-D49), and prior DVT (I82), PE (I26), CVA (I63), and MI (I21)). Most recent body mass index (BMI) data were also collected and (provided a value from at least 1 to 6 months prior to THA was available) stratified into the following categories: <18.5, 18.5 – 24.9, 25 – 29.9, 30 – 34.9, 35 – 39.9, 40 – 49.9, and >50 kg/m2. The categories of race and ethnicity represent socially defined constructs and may reflect patient self-report or administrative assignment at contributing institutions.27 These were included as a matching covariate because prior literature has demonstrated significant racial disparities in OSA prevalence and severity.28,29
Our primary outcome was the proportion of patients with VTE within 28 days of THA, defined as either a DVT or PE ICD-10-CM encounter diagnoses. Secondary outcomes included the individual components of VTE ICD-10-CM encounter diagnoses (DVT and PE separately) as well as CVA and MI ICD-10-CM encounter diagnoses. We analyzed these outcomes both before and after propensity score matching (PSM).
To account for potential confounding factors, we employed the TriNetX platform’s built-in PSM functionality, which utilizes a 1:1 “greedy” nearest-neighbor matching algorithm, which matches each patient from the exposure group (OSA) to exactly 1 patient in the control group (non-OSA) based on the closest propensity score within a specified caliper distance. This distance metric used is the propensity score, which is the probability of OSA diagnosis (defined as ≥1 occurrence prior to THA and ≥2 overall) being assigned given the covariates, and is generated through an implementation of the scikit-learn package.30 The platform’s caliper width is preset within the platform at 0.1 times the pooled standard deviation of the logit of the propensity scores. The matching process incorporated all collected demographic and clinical variables, including the detailed BMI stratification, to generate balanced, matched cohorts. Of note, with regards to missing data, the TriNetX platform reflects information as it is entered into a patient’s EHR during clinical practice, and does not impute to fill any gaps in a patient’s record. We assessed the quality of matching using standardized mean differences (SMDs), with values < 0.1 indicating adequate covariate balance between cohorts.
Statistical significance for risk differences between OSA and non-OSA groups were determined using z-tests with p < 0.05 considered significant. For each outcome, we calculated absolute risk differences (ARDs) with risk ratios and 95% confidence intervals (CI). After PSM, we reassessed these measures to minimize selection bias.
We conducted several supplementary analyses to test the robustness of our findings. These included analyses after dividing the cohorts into five 22-to-23-month periods (10/2015 – 9/2017, 9/2017 – 7/2019, 7/2019 – 5/2021, 5/2021 – 3/2023, 3/2023 – 2/2025). Additionally, we conducted a further exploratory analysis using continuous positive airway pressure (PAP) therapy procedure codes (CPT 94660) as a hypothesis generating effort regarding the impact of PAP on outcome risk: we compared patients with preoperative codes indicating continuous PAP receipt at some point prior to THA (with no specification as to whether they received PAP in time periods following THA) to patients with codes indicating PAP receipt at some point following THA but none prior. We conducted the supplemental PAP analysis in this way to select for similar patients (taking the presence of PAP prescription as a marker of a patient having moderate to severe or at least symptomatic disease) but to discriminate between those more likely to be on PAP pre- and perioperatively (with coding prior to surgery) and those less likely to be so (due to PAP prescriptions appearing only at time points after the intervention). Finally, we performed exploratory analyses using alternative definitions of OSA (including exclusively postoperative OSA diagnostic codes and < 2 occurrences overall of OSA diagnostic codes) for the sake of transparency. This study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.31
Results
Out of a total of 180,734 patients with a CPT code corresponding to THA between 10/01/2015 and 02/01/2025, 20,545 (11%) had a preceding OSA ICD-10-CM encounter diagnosis and met the inclusion criteria as specified in our Methods section, while 146,794 (81%) had no OSA diagnosis at any time point (Figure 1). The remaining 13,395 patients, who either had their first OSA ICD-10-CM encounter diagnosis subsequent to THA or had only a single OSA ICD-10-CM encounter diagnostic code associated with their charts, were excluded from analysis. The demographic and comorbidity data of these two cohorts are summarized in Table 1 both prior to and following 1:1 PSM. There were 19,730 patients in each propensity score-matched cohort (corresponding to a 96% match rate of the OSA cohort) with an absolute standardized mean difference < 0.1 among all covariates, indicating successful matching.
Table 1.
THA patient characteristics
| Cohorts prior to PSM | Cohorts following PSM | |||||
|---|---|---|---|---|---|---|
| OSA | Non-OSA | SMD | OSA | Non-OSA | SMD | |
| Matched covariates / antecedents [ICD-10-CM] | N = 20,545 | N = 146,796 | N = 19,730 | N = 19,730 | ||
| Age at THA (mean ± std dev) | 65.9 ± 10.0 | 65.4 ± 11.8 | 0.050 | 65.9 ± 10.0 | 66.3 ± 10.5 | 0.040 |
| White (%) | 16,020 (78.0) | 113,245 (77.1) | 0.020 | 15,383 (78.0) | 15,420 (78.2) | 0.005 |
| Female (%) | 8,496 (41.4) | 79,146 (53.9) | 0.254 | 8,285 (42.0) | 8,323 (42.2) | 0.004 |
| Hypertension (%) [I10] | 10,307 (50.2) | 34,508 (23.5) | 0.575 | 9,560 (48.5) | 9,878 (50.1) | 0.032 |
| Atrial fibrillation / atrial flutter (%) [I48] | 2,458 (12.0) | 4,784 (3.3) | 0.333 | 2,076 (10.5) | 2,038 (10.3) | 0.006 |
| Heart failure (%) [I50] | 1,696 (8.3) | 2,648 (1.8) | 0.298 | 1,346 (6.8) | 1,206 (6.1) | 0.029 |
| Cerebral infarction (%) [I63] | 306 (1.5) | 820 (0.6) | 0.093 | 270 (1.4) | 256 (1.3) | 0.006 |
| Deep vein thrombosis (%) [I82] | 441 (2.1) | 1,275 (0.9) | 0.105 | 391 (2.0) | 375 (1.9) | 0.006 |
| Pulmonary embolism (%) [I26] | 288 (1.4) | 669 (0.5) | 0.099 | 250 (1.3) | 241 (1.2) | 0.004 |
| Tobacco use (%) [Z72.0] | 336 (1.6) | 1,670 (1.1) | 0.043 | 316 (1.6) | 292 (1.5) | 0.010 |
| Cirrhosis (%) [K74] | 201 (1.0) | 640 (0.4) | 0.065 | 181 (0.9) | 166 (0.8) | 0.008 |
| NAFLD (%) [K76.0] | 529 (2.6) | 966 (0.7) | 0.152 | 444 (2.3) | 428 (2.2) | 0.006 |
| COPD (%) [J44] | 1,636 (8.0) | 3,020 (2.1) | 0.273 | 1,325 (6.7) | 1,177 (6.0) | 0.031 |
| Chronic kidney disease (%) [N18] | 1,787 (8.7) | 4,714 (3.2) | 0.233 | 1,564 (7.9) | 1,563 (7.9) | <0.001 |
| Neoplasia (%) [C00-D49] | 3,241 (15.8) | 14,020 (9.6) | 0.188 | 3,005 (15.2) | 3,121 (15.8) | 0.016 |
| Type 2 diabetes mellitus (%) [E11] | 4,440 (21.6) | 9,592 (6.5) | 0.444 | 3,936 (19.9) | 3,955 (20.0) | 0.002 |
| Hyperlipidemia (%) [E78] | 8,402 (40.9) | 28,028 (19.1) | 0.490 | 7,751 (39.3) | 7,935 (40.2) | 0.019 |
| Myocardial infarction (%) [I21] | 229 (1.1) | 625 (0.4) | 0.079 | 202 (1.0) | 189 (1.0) | 0.007 |
| Most recent BMI (mean ± std dev) | 33.9 ± 6.3 | 29.1 ± 5.7 | 0.802 | 33.6 ± 6.2 | 33.1 ± 6.0 | 0.086 |
| < 18.5 kg/m2 (%) | 72 (0.4) | 1,331 (0.9) | 70 (0.4) | 70 (0.4) | ||
| 18.5 – 24.9 kg/m2 (%) | 1,223 (6.0) | 22,094 (15.1) | 1,219 (6.2) | 1,240 (6.3) | ||
| 25 – 29.9 kg/m2 (%) | 3,951 (19.2) | 33,943 (23.1) | 3,917 (19.9) | 3,927 (19.9) | ||
| 30 – 34.9 kg/m2 (%) | 5,413 (26.3) | 23,550 (16.0) | 5,222 (26.5) | 5,487 (27.8) | ||
| 35 – 39.9 kg/m2 (%) | 4,900 (23.9) | 11,175 (7.6) | 4,404 (22.3) | 4,557 (23.1) | ||
| 40 – 49.9 kg/m2 (%) | 3,167 (15.4) | 4,438 (3.0) | 2,660 (13.5) | 2,529 (12.8) | ||
| > 50 kg/m2 (%) | 244 (1.2) | 255 (0.2) | 176 (0.9) | 153 (0.8) | ||
Abbreviations: BMI – body mass index; COPD – chronic obstructive pulmonary disease; NAFLD – nonalcoholic fatty liver disease; OSA – obstructive sleep apnea; PSM – propensity score matching, SMD – absolute standardized mean difference, and THA – total hip arthroplasty.
Prior to PSM, the ARD between VTE risk in the OSA and non-OSA cohort was 1.2%, corresponding to a RR of 2.0 (95% CI 1.82 – 2.22) (Table 2). All secondary outcomes demonstrated increased risk in the OSA cohort: for PE, the ARD was 0.5% and RR was 2.28 (95% CI 1.94 – 2.67); for DVT, they were 0.8% and 1.90 (95% CI 1.69 – 2.14); for CVA, they were 0.4% and 2.2 (95% CI 1.84 – 2.64), and for MI, they were 0.3% and 1.89 (95% CI 1.56 – 2.30). Following PSM, these measures of association remained significant in the primary outcome of VTE (ARD 0.6%, RR 1.31, 95% CI 1.15 – 1.50) and secondary outcomes of PE (ARD 0.2%, RR 1.29, 95% CI 1.04 – 1.60), DVT (ARD 0.4%, RR 1.28, 95% CI 1.09 – 1.50), and CVA (ARD 0.2%, RR 1.33, 95% CI 1.04 – 1.72), while significance was not retained for the association between OSA and MI.
Table 2.
28-day outcomes following THA of OSA and non-OSA patients
| Outcome variables | Pre-PSM OSA | Pre-PSM non-OSA | Absolute risk difference % (95% CI) | Relative risk (95% CI) |
|---|---|---|---|---|
| N = 20,545 | N = 146,796 | |||
| VTE (%) | 497 (2.4) | 1,768 (1.2) | 1.2 (1.0 – 1.4) | 2.009 (1.82 – 2.22) |
| PE (%) | 199 (1.0) | 624 (0.4) | 0.5 (0.4 – 0.7) | 2.279 (1.94 – 2.67) |
| DVT (%) | 351 (1.7) | 1,320 (0.9) | 0.8 (0.6 – 1.0) | 1.900 (1.69 – 2.14) |
| CVA (%) | 154 (0.7) | 500 (0.3) | 0.4 (0.3 – 0.5) | 2.201 (1.84 – 2.64) |
| MI (%) | 126 (0.6) | 476 (0.3) | 0.3 (0.2 – 0.4) | 1.891 (1.56 – 2.30) |
| Outcome variables | Post-PSM OSA | Post-PSM non-OSA | Absolute risk difference % (95% CI) | Relative risk (95% CI) |
| N = 19,730 | N = 19,730 | |||
| VTE (%) | 472 (2.4) | 360 (1.8) | 0.6 (0.3 – 0.9) | 1.311 (1.15 – 1.50) |
| PE (%) | 185 (0.9) | 144 (0.7) | 0.2 (0.0 – 0.4) | 1.285 (1.03 – 1.60) |
| DVT (%) | 334 (1.7) | 262 (1.3) | 0.4 (0.1 – 0.6) | 1.275 (1.09 – 1.50) |
| CVA (%) | 140 (0.7) | 105 (0.5) | 0.2 (0.0 – 0.3) | 1.333 (1.04 – 1.72) |
| MI (%) | 108 (0.5) | 119 (0.6) | −0.2 (−0.2 – 0.1) | 0.908 (0.70 – 1.18) |
Abbreviations: CI – confidence interval; CVA – stroke; DVT – deep vein thrombosis; MI – myocardial infarction; OSA – obstructive sleep apnea; PE – pulmonary embolism; PSM – propensity score matching, and VTE – venous thromboembolism.
Following these outcome analyses, a number of supplemental analyses were conducted for transparency, namely, using alternative definitions of OSA (as seen in Figure 1); these included an OSA cohort defined by ≥ 1 occurrence of an OSA ICD-10-CM encounter diagnosis (without temporal definition with regards to THA surgery), the definition of OSA as ≥ 1 occurrence of OSA prior to THA (without specifying a minimum number of overall encounter diagnoses of OSA), 1 occurrence or ≥ 2 occurrences of OSA post-THA but none prior, or only a single occurrence of OSA prior to THA. These analyses are disclosed in Supplemental Tables 1 – 5, respectively, and findings were similar to the primary analysis. Exploratory analyses to examine subgroups corresponding to THA surgery between five 22-to-23-month tranches were also conducted (Supplemental Tables 6 – 10). Finally, we conducted an exploratory analysis comparing primary and secondary outcomes between OSA cohorts with CPT-coded evidence of PAP prescription prior to THA and those without (while having CPT-coded evidence for PAP prescription at some time point following THA surgery, Supplemental Table 11). The prescription of PAP prior to surgery was associated with a lower rate of VTE after PSM than in those who were only prescribed PAP at some time point following surgery (RR 1.4, 95% CI 1.01 – 2.00) as was the case with PE (RR 1.70, CI 1.02 – 2.83).
Discussion
Our analysis demonstrated that OSA ICD-10-CM encounter diagnoses before a THA was associated with increased risk of a new VTE ICD-10-CM encounter diagnosis following THA, an association that persisted following rigorous PSM. While the initial unmatched analysis showed increased risks across all vascular outcomes, after PSM the relationship remained significant specifically for VTE and its constituents (DVT and PE), as well as for CVA. The association with MI, while present in the unmatched cohort, did not persist after matching.
These findings align with but also expand upon previous research examining cardiovascular outcomes in surgical patients with OSA.32–34 The relationship between OSA and thrombotic complications has been documented in both non-surgical settings and specific surgical populations.9,10 Previous studies of bariatric surgery patients have shown elevated PE risk in those with OSA, and particularly germane to our work are studies suggesting VTE risk after joint arthroplasty.16–18,35
The pathophysiologic basis for increased thrombotic risk in OSA likely involves multiple mechanisms that affect each component of Virchow’s triad. The intermittent hypoxia characteristic of OSA promotes a hypercoagulable state through impaired fibrinolysis and increased inflammatory mediators.35,36 Changes in blood viscosity and hematocrit contribute to venous stasis.37,38 Additionally, the repeated cycles of desaturation and reoxygenation lead to endothelial dysfunction through nitric-oxide dependent pathways.39,40 These mechanisms are likely compounded by the overlap between risk factors for OSA and VTE, including obesity, advanced age, and reduced mobility.10 To address the potential for obesity to confound or mediate the relationship between OSA and VTE, we incorporated detailed BMI categories into our propensity model, achieving near-equivalent weight distributions across matched cohorts; this should also be anticipated to similarly distribute any BMI-dependent variation in thromboprophylactic dosing between groups.
Our study has several limitations inherent to research using EHR data.21 First, as with all retrospective observational studies, we can only establish associations between OSA and VTE encounter ICD-10-CM diagnostic codes, not causation. Other studies have examined the efficacy of identifying cases of OSA and other sleep diagnoses through administrative data. McIsaac and colleagues reported poor performance of single diagnostic code occurrences, while studies by Laratta and Jolley yielded better results through combinations of codes (up to approximately 90% positive predictive value using 2 outpatient ICD-10-CM encounter diagnoses codes, with greater specificity obtained through additional, OSA-associated factors and comorbidities).24–26 While we attempted to minimize misclassification of OSA status by requiring multiple ICD-10-CM encounter diagnostic codes and excluding patients with new ICD-10-CM encounter diagnoses of OSA after THA, the challenge of OSA underdiagnosis means some patients in our non-OSA cohort may have had unrecognized sleep disordered breathing, which would actually mean that the actual association would be stronger then what we reported. Additionally, the use of discrete data in the contributing EHRs precluded access to important clinical details such as sleep study results and measures of OSA severity. In our exploratory analysis of PAP therapy timing, we observed higher VTE and PE risk in OSA patients without any PAP prescription coding prior to surgery following PSM. While this method cannot be taken to reliably signify PAP utilization, it is nevertheless interesting that after accounting for the higher comorbidity burden of the pre-THA PAP-prescribed group through matching that evidence of pre-existing PAP prescription (and with an inferentially higher likelihood of perioperative PAP receipt) should have fewer VTE diagnostic codes. Finally, we lacked specifics about other aspects of perioperative management, including anticoagulation protocols.
Our large population study adds to the body of evidence associating postsurgical VTE with the presence of OSA, which persisted through extensive PSM. This was made possible through the very large sample we employed, allowing us to comment on the current landscape of highly morbid adverse events in the postoperative period. Further translational and prospective clinical studies will be necessary to explore both the underlying pathophysiology of VTE incidence in patients with OSA and the possibility of developing effective predictive and preventative strategies in high-risk patient subgroups.
Supplementary Material
Funding:
This project was supported in part by the Clinical and Translational Science Collaborative of Northern Ohio, which is funded by the National Institutes of Health, National Center for Advancing Translational Sciences, and Clinical and Translational Science Award grant, UM1TR004528. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The sponsor had no role in the design or conduct of this research.
Abbreviations
- AHI
apnea-hypopnea index
- ARD
absolute risk difference
- BMI
body mass index
- CI
confidence interval
- COPD
chronic obstructive pulmonary disease
- CPT
Current Procedural Terminology®
- CVA
cerebrovascular accident
- DVT
deep vein thrombosis
- EHR
electronic health record
- ICD-10-CM
International Classification of Diseases, Tenth Revision, Clinical Modification
- MI
myocardial infarction
- OSA
obstructive sleep apnea
- PAP
positive airway pressure
- PE
pulmonary embolism
- PSM
propensity score matching
- RR
relative risk
- THA
total hip arthroplasty
- VTE
venous thromboembolism
Footnotes
Conflict of Interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Ethical Approval: As this study exclusively uses deidentified, by expert attestation, Health Insurance Portability and Accountability Act-compliant data from the TriNetX network, it was deemed exempt from review by the Institutional Review Board of Memorial Sloan Kettering Cancer Center. All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Informed Consent: For this retrospective study using deidentified database records, formal informed consent was not required. This article does not contain any identifying information about participants.
Data Availability Statement
The data used in this study were obtained from the TriNetX platform (www.trinetx.com), a federated health research network. The data are not publicly available due to data use agreements and remain accessible only within the TriNetX platform. Researchers may request access to TriNetX by contacting the company directly and establishing institutional data use agreements.
References
- 1.Chang JL, Goldberg AN, Alt JA, et al. International Consensus Statement on Obstructive Sleep Apnea. Int Forum Allergy Rhinol 2023;13(7):1061–1482. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013;177(9):1006–1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. J. Appl. Physiol. 2005;99(4):1592–1599. [DOI] [PubMed] [Google Scholar]
- 4.Memtsoudis SG, Stundner O, Rasul R, et al. The impact of sleep apnea on postoperative utilization of resources and adverse outcomes. Anesth Analg 2014;118(2):407–418. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Kaw R, Chung F, Pasupuleti V, Mehta J, Gay PC, Hernandez AV. Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome. Br J Anaesth 2012;109(6):897–906. [DOI] [PubMed] [Google Scholar]
- 6.Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the u.s., 2014 to 2030. Journal of Bone and Joint Surgery - American Volume 2018;100(17):1455–1460. [DOI] [PubMed] [Google Scholar]
- 7.Wood M, Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Frequency of Myocardial Infarction, Pulmonary Embolism, Deep Venous Thrombosis, and Death following Primary Hip or Knee Arthroplasty. Anesthesiology 2002;96(5):1140–1146. [DOI] [PubMed] [Google Scholar]
- 8.Januel J-M, Chen G, Ruffieux C, et al. Symptomatic In-Hospital Deep Vein Thrombosis and Pulmonary Embolism Following Hip and Knee Arthroplasty Among Patients Receiving Recommended Prophylaxis. JAMA 2012;307(3). [DOI] [PubMed] [Google Scholar]
- 9.Trzepizur W, Gervès-Pinquié C, Heudes B, et al. Sleep Apnea and Incident Unprovoked Venous Thromboembolism: Data from the Pays de la Loire Sleep Cohort. Thromb Haemost 2023;123(04):393–401. [DOI] [PubMed] [Google Scholar]
- 10.Raj R, Paturi A, Ahmed MA, Thomas SE, Gorantla VR. Obstructive Sleep Apnea as a Risk Factor for Venous Thromboembolism: A Systematic Review. Cureus 2022; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Arnulf I, Merino-Andreu M, Perrier A, Birolleau S, Similowski T, Derenne J-P. Obstructive Sleep Apnea and Venous Thromboembolism. JAMA 2002;287(20):2655. [DOI] [PubMed] [Google Scholar]
- 12.Alonso-Fernández A, la Peña M de, Romero D, et al. Association Between Obstructive Sleep Apnea and Pulmonary Embolism. Mayo Clin Proc 2013;88(6):579–587. [DOI] [PubMed] [Google Scholar]
- 13.Epstein MD, Segal LN, Ibrahim SM, Friedman N, Bustami R. Snoring and the Risk of Obstructive Sleep Apnea in Patients with Pulmonary Embolism. Sleep 2010;33(8):1069–1074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Bosanquet JP, Bade BC, Zia MF, et al. Patients With Venous Thromboembolism Appear to Have Higher Prevalence of Obstructive Sleep Apnea Than the General Population. Clinical and Applied Thrombosis/Hemostasis 2011;17(6):E119–E124. [DOI] [PubMed] [Google Scholar]
- 15.Suner KO, Annakkaya AN, Toru U, et al. Is obstructive sleep apnea syndrome a risk factor for pulmonary thromboembolism? Chin Med J 2012;125(20):3712–3718. [PubMed] [Google Scholar]
- 16.D’Apuzzo MR, Browne JA. Obstructive sleep apnea as a risk factor for postoperative complications after revision joint arthroplasty. Journal of Arthroplasty 2012;27(8 SUPPL.):95–98. [DOI] [PubMed] [Google Scholar]
- 17.Tang A, Aggarwal VK, Yoon RS, Liporace FA, Schwarzkopf R. The Effect of Obstructive Sleep Apnea on Venous Thromboembolism Risk in Patients Undergoing Total Joint Arthroplasty. J Am Acad Orthop Surg Glob Res Rev 2022;6(4). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Fowler C, Chawla S, Chism L, Pastores SM, Auckley DH. Risk of Venous Thromboembolism After Total Knee Arthroplasty in Patients with Obstructive Sleep Apnea: Results from a National Cohort. Anesth Analg 2025;141(4):828–835. [DOI] [PubMed] [Google Scholar]
- 19.TriNetX [Internet]. [cited 2024 Dec 4];Available from: https://trinetx.com
- 20.Palchuk MB, London JW, Perez-Rey D, et al. A global federated real-world data and analytics platform for research. JAMIA Open 2023;6(2). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Olaker VR, Fry S, Terebuh P, et al. With big data comes big responsibility: Strategies for utilizing aggregated, standardized, de-identified electronic health record data for research. Clin Transl Sci 2025;18(1):e70093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Fowler C, Nasser J, Fera B, Chism L, Pastores SM. Tranexamic Acid in Upper Gastrointestinal Bleeding is Associated With Venous and Arterial Thromboembolic Events. Crit Care Explor 2024;6(3):e1060. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Lau J, Kaelber DC, Otteson TD. Prevalence of obstructive sleep apnea and related oropharyngeal symptoms in pediatric Ehlers Danlos patients. Int J Pediatr Otorhinolaryngol 2025;195:112460. [DOI] [PubMed] [Google Scholar]
- 24.McIsaac DI, Gershon A, Wijeysundera D, Bryson GL, Badner N, Walraven C van. Identifying Obstructive Sleep Apnea in Administrative Data. Anesthesiology 2015;123(2):253–263. [DOI] [PubMed] [Google Scholar]
- 25.Laratta CR, Tsai WH, Wick J, Pendharkar SR, Johannson KA, Ronksley PE. Validity of administrative data for identification of obstructive sleep apnea. J Sleep Res 2017;26(2):132–138. [DOI] [PubMed] [Google Scholar]
- 26.Jolley RJ, Liang Z, Peng M, et al. Identifying Cases of Sleep Disorders through International Classification of Diseases (ICD) Codes in Administrative Data. Int J Popul Data Sci 2018;3(1). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Flanagin A, Frey T, Christiansen SL. Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals. JAMA 2021;326(7):621. [DOI] [PubMed] [Google Scholar]
- 28.Redline S, Tishler PV, Hans MG, Tosteson TD, Strohl KP, Spry K. Racial differences in sleep-disordered breathing in African-Americans and Caucasians. Am J Respir Crit Care Med 1997;155(1):186–192. [DOI] [PubMed] [Google Scholar]
- 29.Dudley KA, Patel SR. Disparities and genetic risk factors in obstructive sleep apnea. Sleep Med 2016;18:96–102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: machine learning in Python. J Mach Learn Res 2011;(12):2825–2830. [Google Scholar]
- 31.Elm E von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335(7624):806–808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Chan MTV, Wang CY, Seet E, et al. Association of Unrecognized Obstructive Sleep Apnea With Postoperative Cardiovascular Events in Patients Undergoing Major Noncardiac Surgery. JAMA 2019;321(18):1788. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Opperer M, Cozowicz C, Bugada D, et al. Does Obstructive Sleep Apnea Influence Perioperative Outcome? A Qualitative Systematic Review for the Society of Anesthesia and Sleep Medicine Task Force on Preoperative Preparation of Patients with Sleep-Disordered Breathing. Anesth Analg 2016;122(5):1321–1334. [DOI] [PubMed] [Google Scholar]
- 34.Golaz R, Tangel VE, Lui B, Albrecht E, Pryor KO, White RS. Post-operative outcomes and anesthesia type in total hip arthroplasty in patients with obstructive sleep apnea: A retrospective analysis of the State Inpatient Databases. J Clin Anesth 2021;69:110159. [DOI] [PubMed] [Google Scholar]
- 35.Alonso-Fernández A, Toledo-Pons N, García-Río F. Obstructive sleep apnea and venous thromboembolism: Overview of an emerging relationship. Sleep Med Rev 2020;50. [DOI] [PubMed] [Google Scholar]
- 36.Jelic S, Jemtel TH Le. Inflammation, Oxidative Stress, and the Vascular Endothelium in Obstructive Sleep Apnea. Trends Cardiovasc Med 2008;18(7):253–260. [DOI] [PubMed] [Google Scholar]
- 37.Fan Z, Lu X, Long H, Li T, Zhang Y. The association of hemocyte profile and obstructive sleep apnea. J Clin Lab Anal 2019;33(2). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Dikmenoǧlu N, Çiftçi B, Ileri E, et al. Erythrocyte deformability, plasma viscosity and oxidative status in patients with severe obstructive sleep apnea syndrome. Sleep Med 2006;7(3):255–261. [DOI] [PubMed] [Google Scholar]
- 39.Atkeson A, Yeh SY, Malhotra A, Jelic S. Endothelial Function in Obstructive Sleep Apnea. Prog Cardiovasc Dis 2009;51(5):351–362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Ip M, Lam B, Chan L, et al. Circulating Nitric Oxide Is Suppressed in Obstructive Sleep Apnea and Is Reversed by Nasal Continuous Positive Airway Pressure. Am J Respir Crit Care Med 2000;162(6):2166–2171. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data used in this study were obtained from the TriNetX platform (www.trinetx.com), a federated health research network. The data are not publicly available due to data use agreements and remain accessible only within the TriNetX platform. Researchers may request access to TriNetX by contacting the company directly and establishing institutional data use agreements.
